PATHOLOGY
LABORATORY
Female
Reproductive Lab II
Case 1: slide 107
Clinical history: A 20 year old woman saw her gynecologist for symptoms of pelvic pressure and pain. Pelvic examination revealed a large left adnexal mass. The adnexal mass was resected. Examine slide 107.
Case 2: Slide 108
Clinical
history: A 45 year old woman saw her
gynecologist for a feeling of fullness in the left lower quadrant. On pelvic exam a left adnexal mass was
palpated and the mass was resected. The
mass was cystic and contained clear watery fluid. Examine slide 108.
1. What category of the World Health Organization does this neoplasm fit into? Serous tumors (benign, borderline, and malignant) are common epithelial tumors.
Is this
category of neoplasm common? What are these types of neoplasms
derived from? This category
represents about 65% of all primary ovarian neoplasms. Common epithelial neoplasms are derived
from the surface ovarian epithelium which comes from the coelomic epithelium or
mesothelium.
Are malignant forms of this category of neoplasm
common? Malignant common epithelial neoplasms (such as serous,
mucinous, endometrioid, and clear cell carcinomas and malignant Brenner tumors)
represent almost 90% of ovarian carcinomas.
2. This slide contains a serous neoplasm which is a very common type of common epithelial neoplasm.
Serous tumors constitute 50% of all ovarian tumors
and 70% of them are benign, 10% borderline, and 25% are malignant.
Mucinous tumors constitute
20% of all ovarian tumors and 85% are benign, 6% borderline, and 9%
malignant. Most endometrioid tumors are
malignant (benign and borderline tumors are rare) and is the second most common
ovarian cancer.
1. The diagnosis is benign serous cystadenoma of the ovary.
1. Epithelium of the neoplasm resembles the epithelium of the fallopian tube.
1. Benign serous cystadenomas are unilocular or multilocular, thin walled cysts containing watery (serous) fluid.
Case 3: Slide 111
1. Diagnosis is serous cystadenocarcinoma of the ovary. Serous cystadenocarcinomas exhibit obvious stromal invasion and one or more of the following features: fine papillae, irregular often slit-like glandular lumens, small tight nests of tumor cells, solid sheets of tumor and psammoma bodies.
1. Grossly may be cystic and papillary, entirely solid and firm or both cystic and solid. Usually contain friable, necrotic and hemorrhagic areas. Bilateral in 2/3 of cases.
1. FIFO staging of ovarian carcinoma:
Stage I: Limited to ovaries.
Stage II: One or both ovaries and
pelvic extension.
Stage III: One or both ovaries and intraperitoneal
mets outside pelvis (includes superficial liver mets) or positive
retroperitoneal or inguinal lymph nodes.
Stage IV: One or both ovaries and distant mets
(ex. lung, parenchyma of liver).
This case represents a stage III from the
information known since there is involvement of the omentum.
Case 4: Slide 112
1. Diagnosis is borderline serous tumor.
1. Borderline serous tumors have moderate to marked epithelial proliferation shown by nuclear stratification which differentiates it from the benign serous cystadenomas. The lack of destructive stromal invasion differentiates it from serous cystasdenomas. Peritoneal serous proliferations can be present in 20-55% of the cases.
Borderline tumor, stage I: 90%, stage II 80%
Serous carcinoma, stage I: 66%, stage II 15%
1. Mucinous neoplasms are composed of mucin secreting epithelium resembling endocervix, or intestinal epithelium.
Case 5: Slide 38
1. Diagnosis is infiltrating ductal carcinoma.
1. Invasive because tumor cells are not confined within the ductal basement membrane and there is a desmoplastic (scirrhous) stromal response.
1. Ductal (adeno)carcinomas constitute 85% of breast cancers and the majority are scirrhous.
1. Geographic:
USA > far east.
Jews > non-Jews.
Familial: increases
with number of close relatives with breast cancer and with the age the cancer
occurred in the relatives.
Nulliparous > multiparous.
Mother’s age at 1st child > 30 year
(breast feeding early thought to be protective).
Estrogen excess states: obesity, estrogen producing tumors of ovary, exogenous estrogens
(not balanced contraceptive pills)
Hyperplasia and atypical
hyperplasia.
Cancer of contralateral breast or
cancer of the endometrium.
?
increased alcohol consumption.
1. Stage III includes breast cancer of any size with possible skin involvement, pectoral and chest wall fixation and/or nodal involvement including axillary nodes, fixed but without disseminated metastases.
1. Scirrhous: Firm, white, gritty, poorly delineated.
Forms cords
and tubules infiltrating dense stroma.
Medullary: Soft,
fleshy, yellow, well demarcated, “pushing borders”.
Large tumor cells admixed with lymphocytes with
minimal intervening stroma.
Paget’s: Involves
nipple, eczematoid, crusty nodule +/- ulceration.
Characterized by Paget cells in epidermis (large
cells surrounded by clear zone in the epidermis and stain positively for
mucin).
A form of ductal carcinoma that arises from main
lactiferous ducts and extends to involve skin of nipple and areola.
Case 6: Slide 113
1. Diagnosis is fibroadenoma.
1. Well defined nodule composed of fibrous tissue and ducts.
1. Yes, second most common benign pathologic condition. Yes it is neoplastic. It is benign.
1. Cystosarcoma phyllodes or phyllodes tumors are related to fibroadenomas, but are large, bulky tumors in which the stroma differs by being more cellular. The glandular spaces are “leaf-like” and the stromal cells are more plump and larger than regular fibroblasts. Malignancy is present when there are increased mitoses and anaplasia.
Case 7: Slide 114
1. The diagnosis is fibrocystic changes (fibrocystic disease).
1. It is not a neoplasm.
1. Proliferative changes which may be found include epithelial hyperplasia and papillomatosis. Thought to increase risk for carcinoma.
Non-Proliferative
changes
include fibrosis, cyst formation, apocrine metaplasia, and sclerosing
adenosis. Entirely benign and have no
premalignant potential.
Changes present in slide 114 include fibrosis, cyst
formation, apocrine metaplasia, and epithelial hyperplasia.
1. Proliferative changes of epithelial hyperplasia and papillomatosis increase the risk for the development of carcinoma (x2). Atypical hyperplasia further increases the risk (x5).